Literature DB >> 7518081

Multiple myeloma: current treatment.

D Samson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7518081      PMCID： PMC2397727          DOI： 10.1136/pgmj.70.824.404

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


× No keyword cloud information.
  37 in total

1.  Alpha-2a-interferon/melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma.

Authors:  A Montuoro; L De Rosa; A De Blasio; L Pacilli; N Petti; A De Laurenzi
Journal:  Br J Haematol       Date:  1990-11       Impact factor: 6.998

2.  Intensive treatment of multiple myeloma and criteria for complete remission.

Authors:  M E Gore; P J Selby; C Viner; P I Clark; M Meldrum; B Millar; J Bell; J A Maitland; S Milan; I R Judson
Journal:  Lancet       Date:  1989-10-14       Impact factor: 79.321

3.  Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma.

Authors:  D Samson; E Gaminara; A Newland; J Van de Pette; J Kearney; D McCarthy; M Joyner; L Aston; T Mitchell; M Hamon
Journal:  Lancet       Date:  1989-10-14       Impact factor: 79.321

4.  Long-term prognostic value of serum beta 2 microglobulin in myelomatosis.

Authors:  J Cuzick; B L De Stavola; E H Cooper; C Chapman; I C MacLennan
Journal:  Br J Haematol       Date:  1990-08       Impact factor: 6.998

5.  The development of high dose melphalan and of autologous bone marrow transplantation in the treatment of multiple myeloma: Royal Marsden and St Bartholomew's Hospital studies.

Authors:  P Selby; G Zulian; G Forgeson; A Nandi; S Milan; M Meldrum; C Viner; R Osborne; J S Malpas; T J McElwain
Journal:  Hematol Oncol       Date:  1988 Apr-Jun       Impact factor: 5.271

6.  Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy.

Authors:  D J Gottlieb; H G Prentice; H E Heslop; C Bello-Fernandez; A C Bianchi; A R Galazka; M K Brenner
Journal:  Blood       Date:  1989-11-15       Impact factor: 22.113

7.  Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy.

Authors:  F Mandelli; G Avvisati; S Amadori; M Boccadoro; A Gernone; V M Lauta; F Marmont; M T Petrucci; M Tribalto; M L Vegna
Journal:  N Engl J Med       Date:  1990-05-17       Impact factor: 91.245

8.  Erythropoietin treatment of anemia associated with multiple myeloma.

Authors:  H Ludwig; E Fritz; H Kotzmann; P Höcker; H Gisslinger; U Barnas
Journal:  N Engl J Med       Date:  1990-06-14       Impact factor: 91.245

9.  Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma.

Authors:  B Barlogie; W S Velasquez; R Alexanian; F Cabanillas
Journal:  J Clin Oncol       Date:  1989-10       Impact factor: 44.544

10.  Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma.

Authors:  K C Anderson; B A Barut; J Ritz; A S Freedman; T Takvorian; S N Rabinowe; R Soiffer; L Heflin; F Coral; K Dear
Journal:  Blood       Date:  1991-02-15       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.